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Axon regeneration in adult central nervous system (CNS) is limited in part by a developmental decline in the
ability of injured neurons to re-express needed regeneration associated genes (RAGs). Adult CNS neuronsmay
lack appropriate pro-regenerative transcription factors, or may display chromatin structure that restricts
transcriptional access to RAGs. Here we performed epigenetic proﬁling around the promoter regions of key
RAGs, and found progressive restriction across a time course of cortical maturation. These data identify a
potential intrinsic constraint to axon growth in adult CNS neurons. Neurite outgrowth from cultured postnatal
cortical neurons, however, proved insensitive to treatments that improve axon growth in other cell types,
including combinatorial overexpression of AP1 factors, overexpression of histone acetyltransferases, and
pharmacological inhibitors of histone deacetylases. This insensitivity could be due to intermediate chromatin
closure at the time of culture, and highlights important differences in cell culture models used to test potential
pro-regenerative interventions.
© 2016 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).
1. Introduction
Axons in the mammalian central nervous system (CNS) possess low
regenerative capacity, which limits functional recovery fromCNS injuries.
Although external inhibitory cues contribute to regenerative failure
(Yiu and He, 2006; Case and Tessier-Lavigne, 2005), regeneration is also
limited by an intrinsic inability of injured CNS neurons to reactivate
transcriptional programs conducive to re-growth (Goldberg et al., 2002;
Blackmore and Letourneau, 2006; Sun and He, 2010). Transcription
factors are attractive targets to induce regenerative growth since they can
simultaneously regulate the expression of multiple regeneration associ-
ated genes (RAGs). We and others have shown that forced expression of
transcription factors (TFs) can result in regeneration of injured CNS
neurons (Blackmore et al., 2012; Wang et al., 2015; Belin et al., 2015).
However, this regenerative response is limited, highlighting the need to
identify additional strategies to boost the efﬁcacy of pro-regenerative TF
treatments.
Two emerging concepts may explain the limited efﬁcacy of over-
expressing any single pro-regenerative transcription factor. First,
appropriate combinations of TFs may be needed for maximal efﬁcacy.
For example, AP-1 factors JUN and ATF3 have been identiﬁed as hub
TFs in transcriptional networks driving the peripheral nervous system
(PNS) regeneration program, and dual expression results in elevated
growth compared to either alone (Chandran et al., 2016; Fagoe et al.,
2015; Li et al., 2015). Another emerging hypothesis is that the ability
of TFs to activate needed target genes may be constrained at the level
of chromatin structure around key RAGs in CNS neurons (Trakhtenberg
and Goldberg, 2012). Chromatin modiﬁcations including methylation
and acetylation of histone proteins represent well-established mecha-
nisms to regulate gene expression (Bannister and Kouzarides, 2011).
Acetylation, mediated by Histone Acetyltransferases (HATs) gener-
ally leads to a more relaxed, accessible chromatin state, whereas
deacetylation mediated by Histone Deacetylases (HDACs) restricts
DNA accessibility (Yang and Seto, 2007). Importantly, sensory
neurons are known to relax chromatin around key RAGs as they
mount successful regenerative responses to peripheral nerve injury
(Puttagunta et al., 2014). Moreover, pharmacological inhibition of
HDAC activity has been shown to enhance neurite outgrowth and
RAG expression (Gaub et al., 2010; Finelli et al., 2013). Cortical
neurons regenerate axons poorly after injury or stroke, and are
known to undergo an age-dependent decline in regenerative ability
during the early postnatal period (Bregman et al., 1989). Although
existing data from other cell types suggest an important role for
epigenetic regulation, chromatin structure and the phenotypic effects of
histone modiﬁcation remain uncharacterized in cortical neurons.
Hereweexplored the role of combinatorial AP-1 factor expression and
epigenetic status in neurite outgrowth by postnatal cortical neurons, a
Neuroepigenetics 8 (2016) 19–26
⁎ Corresponding author at: Department of Biomedical Sciences, Marquette University,
Milwaukee, WI 53201, USA.
E-mail address: ishwariya.venkatesh@marquette.edu (I. Venkatesh).
http://dx.doi.org/10.1016/j.nepig.2016.10.002
2214-7845/© 2016 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Contents lists available at ScienceDirect
Neuroepigenetics
j ourna l homepage: WWW.ELSEVIER.COM/LOCATE/NEP IG
commonly used model for the study of molecular regulators of axon
growth. First, pairwise combinatorial overexpression of AP-1 factors JUN,
ATF3 and FOS revealed that although JUN overexpression produced
expected increases in neurite length, combinatorial AP-1 expression
produced no synergistic enhancement of outgrowth in this cell type.
Next, proﬁling of the epigenetic landscape around promoter regions
of key RAGs showed progressive chromatin restriction across a time
course of corticalmaturation. Early postnatal cortex showed intermediate
restriction. Interestingly, in contrast to ﬁndings in other cell types, neurite
outgrowth in neurons derived fromearly postnatal cortexwas insensitive
toHAToverexpressionandHDAC inhibition (Puttaguntaet al., 2014;Gaub
et al., 2010). Overall the proﬁling data point toward developmental
restriction of chromatin accessibility at regeneration-associated gene
loci, identifying potential epigenetic constraints to axon growth in adult
neurons. At the same time, thedivergent neurite outgrowthdata illustrate
important differences across cell type in regards to the phenotypic impact
of molecular interventions to enhance axon growth.
2. Methods
2.1. Cloning and plasmid preparation
To create constructs for screening and cell viability experiments,
cDNA encoding JUN, ATF3 and FOSwas prepared (QIAprep SpinMiniprep
Kit, Qiagen 27106) from glycerol stocks of NIH Mammalian Genome
Collection in pSPORT6-CMV expression vectors (Open Biosystems,
ThermoFisher, Huntsville, Alabama) (Gerhard et al., 2004). To create
nuclear-localized reporter constructs, the open reading frame of AP-1
factors (JUN aa1-334; ATF3 aa1-181; FOS aa1-380) was PCR-ampliﬁed
andused to replaceEBFP inexpressionvectorCMV-EBFP-2A-H2B-EGFPas
previously described (Simpson et al., 2015), creating CMV-JUN/ATF3/
FOS-2A-H2B-EGFP. DNA was prepared by EndoFree Plasmid Maxi Kit
(Qiagen 12362) and diluted to 1 μg/μl in endotoxin-free TE buffer.
2.2. Cortical culture, immunohistochemistry, and data analysis
All animal procedures were approved by the Marquette University
Institutional Animal Care and Use Committee. Cortical neurons were
prepared from Sprague Dawley rat pups (Harlan), and procedures for
dissociation, transfection, and neurite outgrowth were performed
as in (Simpson et al., 2015). Brieﬂy, early postnatal (P3–P5) frontal
cortices were dissected, and neurons dissociated. Cells were plated
directly, or transfected then plated at a density of 10,000 cells/well
into 24-well plates pre-coatedwith poly-D-lysine hydrobromide followed
by laminin. Cells were maintained in culture for three days at 37 °C, 5%
CO2 in EnrichedNeurobasal (ENB)media. For neurite outgrowth analysis,
cultures were ﬁxed with 4% PFA (Electron Microscopy Sciences 15710),
and immunohistochemistry was performed for βIII-tubulin. Automated
microscopy acquired images and neurites were traced using Cellomics
Scan v6.4.0 (Thermo Scientiﬁc). Average total neurite length was
quantiﬁed for greater than 100 cells per treatment. For AP-1 imaging,
cells were left untransfected or transfected with CMV-JUN-2A-H2B-EGFP
or CMV-ATF3-2A-H2B-EGFP and ﬁxed after 3 days in culture. Immuno-
histochemistry was performed with DAPI nuclear stain and antibodies
against c-Jun (Santa Cruz Biotechnology sc-1694) or ATF3 (Santa Cruz
Biotechnology sc-188). Cellomics Cell Insight NXT (Thermo Scientiﬁc,
Waltham, MA) acquired images for three channels: nuclear (DAPI),
protein (JUN or ATF3), and reporter (EGFP). Compartmental analysis
quantiﬁed object size and intensity for each channel and data were
exported to Excel for analysis. Fragmented cells were eliminated from
analysis based on DAPI size and intensity, and a transfection threshold
was determined by comparing EGFP intensity to untransfected cells.
Average JUN and ATF3 intensities were reported for n N 250 cells per
treatment. For RAG IHC, P3–P5 cortical neurons were prepared as
described above and ﬁxed at 3 DIV. Immunohistochemistry was
performed with DAPI nuclear stain and antibodies against GAP-43
(abcam ab16053, 1:500) or Galanin (Santa Cruz sc-25446, 1:500) and
βIII-tubulin to identify neurons (Rb-Sigma T2200 (1:500), Ms Stem
cell technologies 600100, 1:2000).
2.3. Pharmacological inhibition of HATs and HDACs
Cortical cultures were incubated for one day before addition of
inhibitor drugs. HDAC inhibitor drugs Trichostatin A (TSA) (Santa
Cruz Biotechnology sc-3511) and Scriptaid (Santa Cruz Biotechnology
sc-202807) were constitutedwith DMSO into 1 mMand 5 mM stocks,
respectively, and diluted to target concentrations in Hibernate E (Life
Technologies A12476-01). HAT inhibitor drugs anacardic acid (Sigma
A7236) and CPTH2 (Sigma C9873) were constituted into 20 mM
stocks in DMSO and diluted to target concentrations in Hibernate E.
Dilutions were done such that addition of 100 μl drug solution to the
500 μl ENB media in each well resulted in the testing concentration of
10 nM, 100 nM, 1 μM, 10 μM and 100 μM for HAT inhibitors and
5 nM, 10 nM, 50 nM, 100 nM and μM for HDAC inhibitors. Cultures
were incubated one additional day before viability assays, or two days
before neurite outgrowth analysis.
2.4. Cell viability assays
Viability assays were modiﬁed from Simpson et al. (2015). Neurons
were transfected with EBFP-2A-mCherry or EBFP-2A-H2B-EGFP,
plated at a density of 10,000 cells/well, and grown in culture for one
day before addition of HAT and HDAC inhibitors, as described above. At
2DIV, media was removed and replaced with 0.01 μM Yo-Pro-1-Iodide
(Cat# C3099, Life Technologies, Waltham, MA) or 0.15 μM propidium
iodide (Cat# P1304MP, Molecular Probes, Eugene, OR), both in PBS
containing 1 μg/ml Hoechst 33342 (Cat# H1399, Molecular Probes,
Eugene,OR), and incubatedat37 °C for30 min. CellomicsCell InsightNXT
(Thermo Scientiﬁc, Waltham, MA) acquired images for three channels:
nuclear (Hoechst 33342), cell death stain (Yo-Pro-1-Iodide or propidium
iodide), and reporter (EBFP-2A-mCherry or EBFP-2A-H2B-EGFP); com-
partmental analysis quantiﬁed intensities for each channel. Percent dead
cells (Hoechst+/Yo-Pro-1-Iodide+ or Hoechst+/propidium iodide+)
was quantiﬁed and subtracted from 100% to report number of live cells
for greater than 1000 cells. Values from 2 to 3 biological replicates was
averaged and analyzed using graphpad prism.
2.5. Quantitative chromatin immunoprecipitation
Motor cortices from female C57BL/6 mice (Harlan) were isolated at
speciﬁed time points (Fig. 3). Freshly dissected cortices were incubated
for 10 min at room temperature with gentle shaking in 1% formalde-
hyde solution (diluted from 16% PFA, Electron microscopy sciences,
Hatﬁeld, PA). The cross-linking reaction was quenched by the addition
of glycine to a ﬁnal concentration of 0.25 M. Cross-linked cells were
washed3 times in lithiumchloridewashbuffer (1.0% Igepal-CA630, 1.0%
deoxycholate,1 mM EDTA,10 mM Tris-HCl (pH 8.1), 250 mM LiCl)
followed by cell lysis in lysis buffer (10 mM Tris-HCl (pH 8.1), 10 mM
NaCl, 1.5 mM MgCl2, 0.5% Igepal-CA630, 5X Roche protease inhibitor
(Cat# 04693132001)). Following lysis, cells were resuspended in
nuclear lysis buffer (50 mM Tris-HCl (pH 8.1), 5 mM EDTA, 1% SDS,
5X protease inhibitor) and subjected to chromatin shearing through
sonication to yield an average of 100–200 bp fragments. Samples were
then incubated with 5 μg antibodies targeting speciﬁc histone modiﬁ-
cations (H3K4me3 antibody – abcam ab8580, H3K4me27-ab6002) or
non-speciﬁc IgG antibody (Cell signaling technology #2729) alongwith
magnetic beads (Cat# 10001D, Thermoﬁsher Scientiﬁc, Waltham, MA)
overnight with gentle shaking at 4 degrees. Samples were then
subjected to reversal of crosslinking, proteinase K digestion, and the
recovered DNA was puriﬁed using Zymo ChIP DNA clean and
concentrator (Cat# D5201, Zymo research Irvine, CA) and subjected to
quantitative PCR.
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2.6. Quantitative real time PCR analysis
Primers used in this study are listed in Supplementary Table 1.
H3K4me3 marks are generally sharply enriched closest to the
transcription start site, and H3K27me3 marks are acquired more
broadly around the promoter and coding regions (Vastenhouw et al.,
2010). Accordingly primer pairs were designed to span as closed to
the transcription site as predicted by Promoter 2.0 software
(Vastenhouw et al., 2010). To assess for relative changes in gene
expression, quantitative PCR (qPCR) was performed on an ABI 7500
Fast Real time PCR system (Applied Biosystems, Carlsbad, CA) with
SYBR green ﬂuorescent label (Quanta Biosciences, Gaithersburg,
MD). A dissociation step was performed at the end of the
ampliﬁcation phase to conﬁrm a single, speciﬁc melting temperature
for each primer set.
Cycle threshold values (Ct) for immunoprecipitated samples for each
RAG was normalized to Ct values from chromatin not subjected to
immunoprecipitation (input) that was diluted 1:100. Speciﬁc enrich-
ment of histone marks to promoters was calculated by subtracting the
noise determined by non-speciﬁc IgG and then normalized to diluted
input. Normalized gene expression data from 3 biological replicates
were averaged and depicted as fold change.
3. Results
3.1. AP-1 factors do not synergize to affect neurite outgrowth in
postnatal cortical neurons
AP-1 factors are widely implicated in axon growth and known to
work interactively to induce pro-regenerative transcriptional pro-
grams (Chandran et al., 2016; Fagoe et al., 2015; Raivich et al., 2004;
Ruff et al., 2012; Makwana et al., 2010; Saijilafu et al., 2011; Fontana et
al., 2012; Lerch et al., 2014; Seijffers et al., 2007; Campbell et al., 2005;
Shokouhi et al., 2010; Saul et al., 2010; Hunt et al., 2012). Speciﬁcally,
ATF3 and JUN show cooperative actions in regulating axon outgrowth
in peripheral neurons (Chandran et al., 2016; Pearson et al., 2003;
Nakagomi et al., 2003; Tsujino et al., 2000). Individual overexpression
of JUN enhances neurite outgrowth in CNS neurons, but it is currently
unknownwhether other AP-1 factorsmay act synergistically with JUN
in this cell type (Lerch et al., 2014).
We therefore adopted a well-established cell culture system to test
co-expression of AP-1 factors JUN, ATF3 and FOS in assays of neurite
outgrowth in post-natal CNS neurons (Simpson et al., 2015; Lerch et
al., 2014; Blackmore et al., 2010; Moore et al., 2009). Post-natal
cortical neurons were transfected in pairwise combinations with a
base plasmid encoding one of the AP-1 factors (JUN, ATF3, FOS) or
EBFP control along with test plasmids encoding JUN, ATF3, FOS, mCh
negative control or DCLK1 positive control (Simpson et al., 2015;
Blackmore et al., 2010). Transfected cells were identiﬁed by EGFP
reporter expressed on base plasmid via a 2A peptide strategy, used
previously for effective co-expression (Simpson et al., 2015;
Blackmore et al., 2010; Tang et al., 2009). Plasmids were delivered
at a ratio of 1 (base plasmid):4 (test plasmid), which results in over
90% co-transfection of both plasmids in EGFP+ cells (Blackmore et al.,
2010). Cells were plated on laminin substrates andmaintained in culture
for 3 days. Automated microscopy quantiﬁed neurite outgrowth from
transfected neurons identiﬁed through βIII-tubulin immunostaining
(Fig. 1C) and EGFP reporter (Fig. 1B). Each combinatorial gene treatment
was tested in four independent experiments, and neurite lengths were
normalized to mCherry control. As previously described (Simpson et al.,
2015; Lerch et al., 2014; Blackmore et al., 2010), overexpression of test
genes JUN and DCLK1 reliably increased neurite outgrowth
(JUN-122.9% ± 5.74%, p-value b 0.05; DCLK1-143.9% ± 11.06%,
p-value b 0.001, ANOVA with post-hoc Dunnett's) conﬁrming assay
sensitivity. Unlike JUN, neither ATF3 nor FOS overexpression increased
neurite lengths. Moreover, no signiﬁcant increases in neurite outgrowth
above single JUN overexpression were observed in any of the combina-
torial AP-1 factor gene treatments (Fig. 1E), including the JUN/ATF3
combination shown previously to produce synergistic gains in outgrowth
from DRG neurons (Chandran et al., 2016). Immunohistochemistry
conﬁrmed robust overexpression of test genes including JUN and ATF3 in
transfected neurons (Fig. 1F–O). In summary, these data indicate that
forced co-expression of AP-1 factors shown to work co-operatively in
peripheral neurons do not synergize to regulate neurite outgrowth in
early cortical neurons.
3.2. Epigenetic proﬁling reveals developmental decrease in promoter
accessibility in CNS neurons as they age in vivo
Besides potential TF/TF interactions, a second emerging concept in
regeneration research is that axon growth may be constrained at the
level of chromatin structure (Trakhtenberg and Goldberg, 2012;
Puttagunta et al., 2014). Fundamentally, transcription of genes needed
for regeneration depends not only on the presence of appropriate
combinations of transcription factors (endogenous or supplied thera-
peutically), but alsoonchromatin structure that allowsTFbinding inkey
promoter regions (Trakhtenberg and Goldberg, 2012; Tedeschi, 2011).
Chromatin accessibility can be predicted by enrichment for speciﬁc
histone marks that are commonly associated with euchromatin
(accessible chromatin) vs heterochromatin (restricted chromatin).
Therefore, as a ﬁrst step in linking regenerative ability to chromatin
structure, we examined histone marks in cortical tissue across a
developmental time-course that spans a period when CNS neurons
are known to decline in regenerative ability (Bregman et al., 1989).
Six RAGs with well-established roles in mediating axon outgrowth
and guidance were selected for initial analysis: gap43, cap23, sprr1a,
integrinα7, hsp27, and galanin (Frey et al., 2000; Bonilla et al., 2002;
Bomze et al., 2001; Zhang et al., 2005; Hobson et al., 2013; Eva and
Fawcett, 2014; Williams et al., 2005; Ma and Willis, 2015). We ﬁrst
examined the histone modiﬁcation H3K4me3, commonly associated
with euchromatin/genomic loci undergoing active transcription,
and H3K27me3, associated with heterochromatin/genomic loci not
actively transcribed (Bannister and Kouzarides, 2011). H3K4me3 and
H3K27me3 marks rarely co-exist around gene promoters and mostly
presence of one modiﬁcation excludes the presence of the other
(Vastenhouw et al., 2010).
In initial validation experiments quantitative chromatin immuno-
precipitation was used to assess the promoter regions of selected RAGs
at E15, an agewhen these genes are actively transcribed (Ma andWillis,
2015). The promoter regions of constitutively expressed gapdh and
non-expressedHoxc10, with previously establishedmethylationmarks,
served as controls. In E15 cortices, the H3K4me3 (“open”) mark was
enriched 15-fold around gapdh locus (p-value b 0.0001 compared to
non-speciﬁc antibody, one-way ANOVA with post-hoc Dunnett's) but
showed no enrichment at the Hoxc10 locus, conﬁrming antibody
efﬁcacy and assay sensitivity (Fig. 2B). H3K4me3 was also highly
enriched at sprr1a, integrinα7, galanin and gap43 loci, consistent with
their embryonic expression (p-value b 0.0001,one-way ANOVA with
post-hoc Dunnett's) (Fig. 2B). In contrast, hsp27 and cap23 gene loci
showed no signiﬁcant enrichment for the H3K4me3mark (Fig. 2B). The
H3K27me3 “closed”markwasenriched14-fold around theHoxc10 gene
locus (p-value b 0.0001, one-way ANOVAwith post-hoc Dunnett's) but
was not signiﬁcantly enriched at the gapdh locus, again conﬁrming the
expected antibody behavior (Fig. 2C). Consistent with high embryonic
expression, none of the RAG gene loci showed enrichment for the
H3K27me3 mark (Fig. 2C). These experiments conﬁrm that the chosen
histone marks H3K4me3 and H3K27me3 reliably correlate with
euchromatin/heterochromatin in four of the six gene loci examined in
E15 cortices, and can be used to detect chromatin accessibility around
these loci. Promoters for hsp27 and cap23 do not show enrichmentwith
either histonemark, suggesting that other histonemodiﬁcationsmay be
associated with these gene loci. Further analyses were restricted only
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Fig. 1. JUN mediated enhancement of neurite outgrowth is not increased by AP-1 factor co-expression. P3 cortical neurons were co-transfected with plasmid DNA and cultured on
laminin substrates for 3 days. (A–D) Images were acquired through automated microscopy (Nuclear: DAPI, Neuronal: βIII-tubulin, Transfection: EGFP). Cells positive for
neuron-speciﬁc βIII-tubulin and EGFP (arrows, B and C) were used for subsequent analyses. (E) Bars show the average neurite length in cells expressing combinations of AP-1
transcription factors normalized to mCherry control. Test genes included DCLK1 and JUN, both of which showed expected changes in neurite length, conﬁrming assay sensitivity.
*p-Value b .05 ANOVA with post-hoc Dunnett's, N N 100 cells in three replicate experiments, error bars represent SEM, F-value-1.32. Scale bar is 50 μm. (F–O) P3 cortical neurons
were transfected with ATF3-EGFP (F–I) or JUN-EGFP (K–O) reporter plasmids and cultured on laminin substrates for 3 days. Cells were then stained with antibodies targeting ATF3/
JUN followed by automated compartmental analysis to compare ATF3/JUN intensities in untransfected cells vs transfected cells within the samewell. J,O - Bars show average ATF3 (J)
or JUN (O) ﬂuorescence intensities in untransfected cells and cells transfected with plasmids to overexpress ATF3 or JUN. ****p-Value b 0.0001 unpaired t-test, N N 1000 cells, error
bars represent SEM.
Fig. 2.Genomic loci corresponding to regeneration associated genes are associated with open chromatin during development. RAG promoter sequences were enriched by ChIP in E15
cortex using antibodies targeted to open and closed chromatin marks. Speciﬁc enrichment of histone marks to promoters is calculated by subtracting the noise determined by
non-speciﬁc IgG and then normalized to diluted input. Dotted line represents relative fold enrichment observed in non-speciﬁc IgG control (A) Experimental schematic outlining the
epigenetic proﬁling experiment across age as CNS neurons mature in vivo (B) Signiﬁcant fold enrichment over non-speciﬁc background is observed in 4 of the RAG promoter
sequences for the H3K4me3 (open chromatin) histone mark, comparable to positive control gapdh locus (p-value b 0.0001, one-way ANOVA with post-hoc). No signiﬁcant
enrichment over background is observed in Hoxc10 (neg ctrl), hsp27 or cap23 loci. (C) No signiﬁcant enrichment over non-speciﬁc background is observed for H3K27me3 mark in
any of the RAG loci proﬁled. Hoxc10 (p-value b 0.001, one-way ANOVA with post-hoc) and gapdh loci serve as positive and negative controls for the H3K27me3 modiﬁcation,
conﬁrming antibody speciﬁcity. Error bars represent SEM. N = 2–3 biological replicates.
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to the four RAGs that showed signiﬁcant enrichment for H3K4me3
mark in E15 cortices.
We then investigated changes in chromatin state around pro-
moters of the selected RAGs over a time series of cortical maturation
in vivo (E15, P3, P7, P14, P21, and adult). When examining the
H3K4me3 open chromatin mark, the gapdh locus displayed ~15-fold
enrichment at all ages, consistent with its continual expression. In
contrast, the sprr1a, integrinα7, galanin and gap43 loci showed a
~2-fold decrease (p-value b 0.001, two-way ANOVA with post-hoc
Dunnett's) between E15 and P7, followed by a gradual decline, to
levels in adulthood there were not signiﬁcantly higher than
background signal (Fig. 3). The H3K27me3 “closed” mark was highly
enriched at the Hoxc10, but not gapdh, at all ages (Fig. 4). All four
RAGs displayed a signiﬁcant increase in enrichment for H3K27me3
with age, with ~15-fold increase in the adult cortex compared to
embryonic (p-value b 0.00001, two-way ANOVA with post-hoc
Dunnett's). Interestingly, there were differences in the timing of this
transition among the RAGs, with some RAGs showing enrichment for
closed chromatin mark as early as P3 (sprr1a), and others gaining
enrichment at P7 (gap43), P21 (integrinα7) and only in adult cortex
(galanin) (Fig. 4). Overall these experiments demonstrate increase in
restricted chromatin around promoters of key RAGs as CNS neurons
mature in vivo, identifying a potential constraint limiting the intrinsic
regenerative capacity of CNS neurons.
3.3. Global manipulation of HDAC/HAT activity does not enhance neurite
outgrowth in post-natal CNS neurons
Chromatin accessibility is gated by acetylation of histones,
modulated by the opposing actions of Histone Acetyltransferases
(HATs) and Histone Deacetylases (HDACs) (Lee andWorkman, 2007).
HAT-mediated acetylation of histones generally leads to a more
relaxed, accessible chromatin state, whereas HDAC-mediated deace-
tylation restricts DNA accessibility. Overexpression of HATs and/or
inhibition of HDAC activity, both predicted to lead to a more relaxed
chromatin state, have been shown to promote increased RAG
transcription and axon regeneration in sensory neurons (Puttagunta
et al., 2014; Finelli et al., 2013; Lv et al., 2012; Lv et al., 2011). Early
postnatal cortical neurons are widely used as a tractable model for the
study of the molecular control of axon growth (Simpson et al., 2015;
Lerch et al., 2014; Blackmore et al., 2010; Zou et al., 2015), but it is
currently unknown how theymight respond to global manipulation of
HAT or HDAC activity.
We ﬁrst tested forced expression of two well-studied HATs, or
KAT2B (PCAF), in post-natal cortical neurons. All constructs expressed
an EGFP reporter via 2A peptide, and were co-expressed with either
mCherry or DCLK1 as a positive control for growth promotion. Cells
were maintained in culture for 3 days, then ﬁxed and subjected to
automated tracing of neurite length as described above. As expected,
DCLK1 expression robustly increased neurite length compared to
EBFP control (EBFP + DCLK1-143.9% ± 11.06%, p-value b 0.001,
One-way ANOVA with post-hoc Dunnett's). In contrast, KAT2A and
KAT2B expression had no effect on neurite length, either in basal
conditions or when combined with DCLK1 (Fig. 5A). Thus, forced
over-expression of HATs-KAT2A/KAT2B does not promote in-
creased neurite outgrowth in early CNS neurons. This is in contrast
to what is observed in the PNS, wherein overexpression of KAT2B
alone was sufﬁcient to promote axon outgrowth to levels compa-
rable to the well-studied conditioned-lesion paradigm (Puttagunta
et al., 2014).
We next tested pharmacological manipulation of HDAC and HAT
activity. First, broad-spectrum HDAC inhibitors TSA and Scriptaid were
applied to post-natal cortical neurons in concentrations between 5
and 50 nM, previously shown to increase neurite outgrowth in other
neuronal cell types (Gaub et al., 2010; Finelli et al., 2013). HDAC
inhibitors at these concentrations are not expected to affect cell
survival (Gaub et al., 2010), and indeed viability assays showed no
effects at concentrationsbelow100 nM(Fig. S1). Cellswere subjected to
automated neurite tracing two days post-inhibitor treatment, with
neurite lengths normalized to untreated cells. Interestingly, we did not
observe any enhancement in neurite outgrowth at any concentration
of HDAC inhibitors (Fig. 5B). In complementary experiments,
broad-spectrum inhibitors of HAT activity were also tested, to evaluate
effects of blockingHAT activity onnet neurite outgrowth. Anacardic acid
(AA) and CPTH2 were applied to post-natal cortical neurons in
Fig. 3. Promoter regions of RAGs show reduced enrichment for open chromatin as CNS
neurons mature in vivo. RAG promoter sequences were enriched by ChIP in cortices
across age using antibodies targeted to euchromatin mark- H3K4me3. Speciﬁc
enrichment of histone marks to promoters is calculated by subtracting the noise
determined by non-speciﬁc IgG and then normalized to diluted input. Gapdh gene locus
shows signiﬁcant enrichment for H3K4me3 mark across all ages, conﬁrming antibody
efﬁcacy and speciﬁcity. Signiﬁcant fold enrichment for H3K4me3 is observed in E15
cortex across all genes comparable to gapdh positive control locus (p-value b 0.0001,
one-way ANOVA with post-hoc Dunnett's). For 2 of the RAGs - sprr1a and integrinα7,
there was a signiﬁcant reduction in enrichment of H3K4me3 mark between E15 and P3
(p-value b 0.01, two-way ANOVA with post-hoc Dunnett's), with most all genes
showing signiﬁcant reduction in enrichment for open chromatin between E15 and
P7(***p-value b 0.001, two-way ANOVA with post-hoc Dunnett's), with the most
signiﬁcant reduction in enrichment observed between E15 and P14 - adult cortex
(p-value b 0.0001, two-way ANOVA with post-hoc Dunnett's). F-value-207.7, error
bars represent SEM. N = 2–3 biological replicates.
Fig. 4. Promoter regions of RAGs associated with heterochromatin in the adult cortex
RAG promoter sequences were enriched by ChIP in cortices across age using antibodies
targeted to heterochromatin mark - H3K4me27. Speciﬁc enrichment of histone marks
to promoters was calculated by subtracting the noise determined by non-speciﬁc IgG
and then normalized to diluted input. Hoxc10 gene locus shows signiﬁcant enrichment
for H3K27me3 mark across all ages, conﬁrming antibody efﬁcacy and speciﬁcity.
Enrichment for closed chromatin mark is not signiﬁcant over background at E15 for any
of the RAGs. Gene loci gain enrichment for closed chromatin mark as neurons age, with
the most signiﬁcant fold enrichment for H3K4me27 mark observed in adult cortex.
Levels of H3K27me3 enrichment in adult cortex for all genes are comparable to Hoxc10
positive control locus (p-value b 0.0001, one-way ANOVA with post-hoc Dunnett's).
F-value-169. Error bars represent SEM. N = 2–3 biological replicates.
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increasing concentrations as previously described (Lin et al., 2015).
Again, automated analysis of neurite lengths detected no signiﬁcant
effect on neurite outgrowth at any of the concentrations tested (Fig. 5C).
Cell viability assays conﬁrmed no effects on cell survival at the tested
concentrations (Fig. S1). Thus postnatal cortical neurons, derived from
an age at which chromatin marks indicate intermediate accessibility at
key RAGs, appear to display neurite outgrowth that is insensitive to
global pharmacological inhibitors of HDAC and HAT activity.
4. Discussion
Here we examined chromatin modiﬁcations in the maturing
cortex and evaluated two emerging strategies to promote neurite
outgrowth in cultured cortical neurons. In contrast to previous reports
in other cell types, we found that neither combinatorial overexpres-
sion of AP-1 factors nor treatments that target histone acetylation
affected neurite outgrowth in this assay system. At the same time we
detected progressive chromatin restriction around promoters of
crucial RAGs as the cortex matures in vivo, and found chromatin
restriction to be in an intermediate state at the early postnatal period.
Thus, in the adult, chromatin restriction may represent an intrinsic
constraint that could limit the regenerative capacity of CNS neurons,
highlighting the need to optimize targeted genetic/epigenetic
combinatorial manipulations to boost the intrinsic capacity of CNS
neurons. On the other hand, although postnatal CNS neurons are
widely used as a model to investigate the molecular control of axon
growth, their capacity for neurite extension appears to be insensitive
to commonly used strategies to alter acetylation.
4.1. Combinatorial TF treatments – differential requirements in CNS vs
PNS
Identifying optimal TF/TF combinations is an important research
goal in regenerative research. Although we and others have shown
that forced expression of single pro-regenerative TFs can act to
enhance axon regeneration in injured CNS neurons (Blackmore et al.,
2012; Wang et al., 2015; Belin et al., 2015), it is increasingly clear that
combinatorial TF treatments are more effective than single TF
treatments (Belin et al., 2015; Sun et al., 2011; Jin et al., 2015). Indeed,
in silico analyses of peripheral neurons indicates that multi-nodal
transcriptional networks, rather than isolated activities by individual
TFs, drives regenerative axon growth (Chandran et al., 2016; Li et al.,
2015; Tedeschi, 2011; van Kesteren et al., 2011; Geeven et al., 2011;
Michaelevski et al., 2010). AP-1 factors JUN and ATF3 are classic
regeneration-associated TFs, likely involved in coordinating the periph-
eral nerve regeneration program based on their expression patterns
in transcriptional proﬁling datasets (Blackmore, 2012). Forced
over-expression of JUN enhances neurite outgrowth in post-natal
cortical neurons (Lerch et al., 2014) and constitutive overexpression
of ATF3 is known to enhance peripheral nerve regeneration (Seijffers et
al., 2007). Since these factors are predicted to work cooperatively to
drive RAG gene expression in injured neurons (Pearson et al., 2003;
Nakagomi et al., 2003; Tsujino et al., 2000), there is a strongpossibility of
synergy in regulating neurite outgrowth. Indeed, in a recent study in
cultured peripheral neurons, ATF3/JUN combinations promoted neurite
outgrowth to a greater extent than either factor alone (Chandran et al.,
2016).
Thus it is somewhat unexpected that in postnatal cortical neurons,
pairwise overexpression of JUN, ATF3, or FOS did not lead to further
increases in neurite outgrowth above JUN alone (Fig. 1). What could
explain this lack of synergy? It is possible that AP-1 factors show
functional redundancy in activating downstream RAGs in early
post-natal CNS neurons. A second possibility is that AP-1 factors may
function in a cell-type speciﬁc manner to promote growth, depending
on the availability of molecular components that may interact with or
modify JUN/ATF3 to render them functional. For instance JNKs are
activated in response to stress/axotomyand are required to activate JUN
and ATF3 and such upstream regulators may be naturally available in a
DRG cellular context, but missing in CNS neurons limiting full efﬁcacy
of these factors (Coffey, 2014). Lastly, it is possible that the stoichiom-
etry of the co-expressed factors, which is not well controlled in
this overexpression paradigm, may favor the formation of homo- or
heterodimers that interferewithpro-regenerative function.AP-1 factors
are known to form both homo- and heterodimers that differ greatly in
transcriptional activity, and in some cases AP-1 homodimer formation
can even lead to hampered/repressed target gene expression
(Nakagomi et al., 2003; Hai and Hartman, 2001). Thus it is possible
that an optimal ratio of JUN/ATF3 expression is needed for efﬁcient axon
growth, but was not achieved by the plasmid co-transfection strategy
used in this study. These possibilities highlight the complexity in
successfully recapitulating PNS regeneration speciﬁc transcriptional
networks in a CNS context, and identify important factors to take into
Fig. 5. Global manipulation of HAT/HDAC activity does not enhance neurite outgrowth in post-natal cortical neurons. (A) P3 cortical neurons were co-transfected with plasmids to
overexpress HATs (KAT2A, KAT2B) or control plasmids (EBFP), along with mCh negative control and DCLK1 and cultured on laminin substrates for 3 days. Images were acquired
through automated microscopy and tracing quantiﬁed neurite length. Bars show the average neurite length in cells overexpressing HATs normalized to mCherry control. mCh and
DCLK1 controls showed expected changes in neurite length in both HAT combinations, conﬁrming assay sensitivity. (B) P3 cortical neurons were cultured on laminin substrates and
Class I and II HDAC pharmacological inhibitors Trichostatin A (TSA) and Scriptaid were added 1DIV in increasing concentrations (0,5,10,50 nM) and allowed to incubate for 2 days
before automated neurite outgrowth analysis. Bars show the average neurite length in cells treated with HDAC inhibitors normalized to no treatment (C) P3 cortical neurons were
cultured on laminin substrates and Class I and II HAT pharmacological inhibitors Anarcardic acid (AA) and CPTH2 were added 1DIV in increasing concentrations (0,5,10,50 nM) and
allowed to incubate for 2 days before automated neurite outgrowth analysis. Bars show the average neurite length in cells treated with HAT inhibitors and normalized to no
treatment. For all experiments, n N 100 cells (three biological replicates), error bars represent SEM.
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accountwhen designing efﬁcient combinatorial gene treatments in CNS
neurons.
4.2. Epigenetic manipulation of axon growth
Our data also offer circumstantial support for the emerging
hypothesis that a major barrier to initiating a pro-growth genetic
program in CNS neurons exists at the level of the DNA, that is, at the
level of chromatin structure. It is well established that many CNS
neurons, including those in the cortex, decline in their intrinsic
regenerative ability during postnatal development (Goldberg et al.,
2002; Bregman et al., 1989; Moore et al., 2009; Chen et al., 1995;
Dusart et al., 1997). A central feature of this reduced regenerative
ability is the developmental reduction in expression of key RAGs
(Karimi-Abdolrezaee et al., 2002), and a frequent failure to re-express
those RAGs after axotomy (Plunet et al., 2002; Mason et al., 2003). The
current data show pronounced changes in histone marks in RAG
promoter regions, indicative of progressive chromatin closure during
postnatal development. For atleast one RAG, GAP-43, the acquisition of
“closed” chromatinmarks correlatewellwith observedmRNAexpression
patterns across age in corticospinal motor neurons (Karimi-Abdolrezaee
et al., 2002). A major caveat to this ﬁnding regards the use of whole
cortical tissue, as opposed topuriﬁedneurons. It is possible that chromatin
changes in non-neural cells and/or developmental shifts in the cellular
compositionof the cortex could contribute to theobservedchanges.Given
the high neuronal proportion in the overall cortical cell population,
however, it is quite unlikely that the magnitude of the near-complete
reversal of theH3K4me3andH3K27me3markswithagecanbeexplained
entirely by shifts in non-neuronal cells. This is especially true considering
the known neural-speciﬁc expression of these RAGs (Ma and Willis,
2015). Thepuriﬁcationofneurons frommature cortex is quite challenging
and outside the technical scope of this manuscript. Thus, although
deﬁnitive conclusions must await the analysis of puriﬁed neurons, the
current data provide a very strong indication that chromatin structure at
genes involved in regenerative axon growth undergoes profound
restriction as neurons age.
To test the emerging link between chromatin structure and axon
growth, previous studies have genetically or pharmacologically
manipulated chromatin accessibility in functional assays of axon
growth. Genes that are not actively transcribed, such as RAGs in
non-regenerating CNS neurons, may be held in a “closed” chromatin
state, rendering them inaccessible to transcription factors (Trakhten-
berg and Goldberg, 2012). One of the best-characterized and readily
manipulated epigenetic modiﬁcations is acetylation of histones,
mediated by Histone Acetyltransferases (HATs) and Histone Deacety-
lases (HDACs). In the simplest model, acetylation mediated by HATs
leads to a more relaxed chromatin state with increased accessibility to
DNA-binding regions and deacetylation mediated by HDACs leads to a
restricted chromatin state, blocking DNA accessibility (Yang and
Seto, 2007; Cho and Cavalli, 2014). Consistent with this, experiments
in cerebellar granular neurons found thatmanipulation of HDAC/HAT
enzyme activity to favor open relaxed chromatin enhanced RAG
transcription and also modestly improved neurite outgrowth (Gaub
et al., 2010). Also, studies have shown that inhibition of HDAC
activity results in increased RAG gene transcription, peripheral nerve
outgrowth and improved behavior in mice challenged with spinal
injuries (Finelli et al., 2013; Lv et al., 2012; Lv et al., 2011; Lee et al.,
2012). Furthermore, in regeneration-competent neurons, axonal injury
triggers relaxation of chromatin at key loci corresponding to crucial
RAGs (Puttagunta et al., 2014). However, we ﬁnd that overexpression
of HATs-KAT2A and KAT2B/pharmacological inhibition of Class I or II
HDAC activities in early post-natal cortical neurons does not lead to
signiﬁcant enhancement in neurite outgrowth.
What could explain the lack of effects uponmanipulation of HDAC/
HAT activity in early post-natal CNS neurons? First, our epigenetic
proﬁling experiments indicate that in the early postnatal cortex, RAG
promoters show decreased accessibility compared to embryonic
immature neurons, but the restriction is not as severe as what is
observed in adult neurons. It could be that in neurons prepared at this
age, chromatin structure around key RAG promoters does not yet limit
access, negating the need for additional treatments to relax
chromatin. This is especially relevant because chromatin restriction
genome-wide has been shown to proceed at a slower pace when
cells are maintained in vitro, than what is observed in an in vivo
environment (Frank et al., 2015). Consistent with this, we observe
clear RAG expression for GAP-43, Galanin in early post-natal neurons
maintained in vitro (Fig. S2), same age as the cells used in the HDAC/
HATi experiments. The use of fully adult CNS neurons in cell culture
models of axon growth is largely prevented by poor viability, and
therefore embryonic or early postnatal cells are typically used. Hence
although post-natal cortical neurons have proven to be a highly
effective model in which to identify genes important for axon growth
(Simpson et al., 2015; Blackmore et al., 2010), older neurons
maintained in culture may be more suited for epigenetic screening
studies.
Another possibility for lack of effects upon broad manipulation of
HDAC/HAT activity involves non-speciﬁcity. It is well known that
chromatin remodeling complexes and histone-modifying enzymes
act widely across the eukaryotic genome (Langst and Manelyte,
2015; Nemeth and Langst, 2004). Although engaging HATs and
HDACs to alter chromatin structure is an obvious approach to relieve
epigenetic constraints, non-speciﬁc effects of global overexpression/
inhibition must be considered. In line with this, research in cell
re-programming and nervous system development has revealed that it
is not the absolute expression levels of HATs/HDACs, but rather how
these chromatin remodelers are directed to relevant genomic loci that
determines successful downstream gene transcription via targeted
chromatin remodeling (Frank et al., 2015; Koche et al., 2011). In addition,
non-histone targets of HATs and HDACs must also be considered. For
example, HATs are also known to target microtubules in the axoplasm.
Thus, although HAT inhibition might be expected to close chromatin
and thereby restrict axon growth, in fact HAT inhibition can increase
neurite outgrowth in DRG neurons, a ﬁnding that may be explained by
microtubule stabilization (Lin and Smith, 2015). Thus amajor and unmet
challenge regarding epigenetic modulation may be the need to develop
more precise targeting strategies, such that relevant chromatin remo-
delers are directed to the precise genomic loci for targeted chromatin
remodeling.
Overall we report ﬁndings that hint at potential strategies going
forward to boost intrinsic regenerative capacity in CNSneurons (Yiu and
He, 2006). Early developmental genetic interventions may be more
successful in triggering pro-regenerative gene cascades, since adult
neurons display constricted chromatin around key RAG promoters
(Case and Tessier-Lavigne, 2005). Combining targeted chromatin
remodeling with pro-regenerative TFs may be necessary to allow full
efﬁcacy of transcription factor treatments (Goldberg et al., 2002).
Although combinatorial transcription factor treatments are likely better
than individual treatments, the lack of AP-1 synergy in the present
experiments highlight differences across cell type in the potential
efﬁcacy of identiﬁed transcriptional modules.
Supplementary data to this article can be found online at doi:10.
1016/j.nepig.2016.10.002.
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